Kranz DM - Search Results

1

Experimental manipulations of afferent immune responses influence efferent immune responses to brain tumors.

Thomas DL, Kranz DM, Roy EJ. Thomas DL, et al. Among authors: kranz dm. Cancer Immunol Immunother. 2008 Sep;57(9):1323-33. doi: 10.1007/s00262-008-0467-8. Epub 2008 Feb 16. Cancer Immunol Immunother. 2008. PMID: 18278494 Free PMC article.

2

Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis.

Kranz DM, Patrick TA, Brigle KE, Spinella MJ, Roy EJ. Kranz DM, et al. Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9057-61. doi: 10.1073/pnas.92.20.9057. Proc Natl Acad Sci U S A. 1995. PMID: 7568072 Free PMC article.

3

Folate receptors as potential therapeutic targets in choroid plexus tumors of SV40 transgenic mice.

Patrick TA, Kranz DM, van Dyke TA, Roy EJ. Patrick TA, et al. Among authors: kranz dm. J Neurooncol. 1997 Apr;32(2):111-23. doi: 10.1023/a:1005713115147. J Neurooncol. 1997. PMID: 9120540

4

Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells.

Cho BK, Roy EJ, Patrick TA, Kranz DM. Cho BK, et al. Among authors: kranz dm. Bioconjug Chem. 1997 May-Jun;8(3):338-46. doi: 10.1021/bc9700244. Bioconjug Chem. 1997. PMID: 9177839

5

Targeting T cells against brain tumors with a bispecific ligand-antibody conjugate.

Roy EJ, Cho BK, Rund LA, Patrick TA, Kranz DM. Roy EJ, et al. Among authors: kranz dm. Int J Cancer. 1998 May 29;76(5):761-6. doi: 10.1002/(sici)1097-0215(19980529)76:5<761::aid-ijc23>3.0.co;2-5. Int J Cancer. 1998. PMID: 9610737

6

Targeting tumor cells with bispecific antibodies and T cells.

Kranz DM, Manning TC, Rund LA, Cho BK, Gruber MM, Roy EJ. Kranz DM, et al. J Control Release. 1998 Apr 30;53(1-3):77-84. doi: 10.1016/s0168-3659(97)00239-3. J Control Release. 1998. PMID: 9741915

7

Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors.

Patrick TA, Kranz DM, Zachary JF, Roy EJ. Patrick TA, et al. Among authors: kranz dm. Int J Cancer. 1998 Nov 9;78(4):470-9. doi: 10.1002/(sici)1097-0215(19981109)78:4<470::aid-ijc13>3.0.co;2-a. Int J Cancer. 1998. PMID: 9797136

8

Bispecific agents target endogenous murine T cells against human tumor xenografts.

Rund LA, Cho BK, Manning TC, Holler PD, Roy EJ, Kranz DM. Rund LA, et al. Among authors: kranz dm. Int J Cancer. 1999 Sep 24;83(1):141-9. doi: 10.1002/(sici)1097-0215(19990924)83:1<141::aid-ijc24>3.0.co;2-0. Int J Cancer. 1999. PMID: 10449621

9

IL-12 treatment of endogenously arising murine brain tumors.

Roy EJ, Gawlick U, Orr BA, Rund LA, Webb AG, Kranz DM. Roy EJ, et al. Among authors: kranz dm. J Immunol. 2000 Dec 15;165(12):7293-9. doi: 10.4049/jimmunol.165.12.7293. J Immunol. 2000. PMID: 11120864

10

Rapid method for measuring ScFv thermal stability by yeast surface display.

Orr BA, Carr LM, Wittrup KD, Roy EJ, Kranz DM. Orr BA, et al. Among authors: kranz dm. Biotechnol Prog. 2003 Mar-Apr;19(2):631-8. doi: 10.1021/bp0200797. Biotechnol Prog. 2003. PMID: 12675608

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

214 results

Search Page

Filters